Wilson HTM published yesterday.
They have a 12 month price target of about $1.61 (from memory)
They are assuming that BTA licences LANI for ROW and that a 15% royalty is shared by BTA and DS.
They are assigning a 75% probability to LANI getting FDA approval.
IN OTHER WORDS - THE WILSON HTM TEAM does not recognise that BTA now plans to manage stockpile sales itself, capturing the bulk of the spoils for BTA (and DS).
I think that this is SLOPPY RESEARCH.
- Forums
- ASX - By Stock
- BTA
- biota will enjoy all the spoils-the australian
biota will enjoy all the spoils-the australian, page-6
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)